APA (7th ed.) Citation

Reid Thompson, W., Hornby, B., Manuel, R., Bradley, E., Laux, J., Carr, J., & Vernon, H. J. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in medicine, 23(3), 471-478. https://doi.org/10.1038/s41436-020-01006-8

Chicago Style (17th ed.) Citation

Reid Thompson, W., Brittany Hornby, Ryan Manuel, Elena Bradley, Janice Laux, Jim Carr, and Hilary J. Vernon. "A Phase 2/3 Randomized Clinical Trial Followed by an Open-label Extension to Evaluate the Effectiveness of Elamipretide in Barth Syndrome, a Genetic Disorder of Mitochondrial Cardiolipin Metabolism." Genetics in Medicine 23, no. 3 (2021): 471-478. https://doi.org/10.1038/s41436-020-01006-8.

MLA (9th ed.) Citation

Reid Thompson, W., et al. "A Phase 2/3 Randomized Clinical Trial Followed by an Open-label Extension to Evaluate the Effectiveness of Elamipretide in Barth Syndrome, a Genetic Disorder of Mitochondrial Cardiolipin Metabolism." Genetics in Medicine, vol. 23, no. 3, 2021, pp. 471-478, https://doi.org/10.1038/s41436-020-01006-8.